Nano Science and Technology Institute - NSTI  
Nano Science and Technology Institute   Home | Subscribe | Site Map  
  ABOUT | COURSES | EVENTS | PUBLICATIONS | LEADERSHIP | OUTREACH | NEWS | PRESS | JOBS | Nanotechnology Solutions
px
px fade_top
Publications
Nanotech 2008 CDROM
Nanotech 2007 CDROM
Nanotech 2006 CDROM
Nanotech 2005 CDROM
Nanotech 2004 CDROM
3 CDROM Special Offer
Nanotech 2008 Vol. 1
Nanotech 2008 Vol. 2
Nanotech 2008 Vol. 3
Nanotech 2007 Vol. 1
Nanotech 2007 Vol. 2
Nanotech 2007 Vol. 3
Nanotech 2007 Vol. 4
Nanotech 2006 Vol. 1
Nanotech 2006 Vol. 2
Nanotech 2006 Vol. 3
Nanotech 2005 Vol. 1
Nanotech 2005 Vol. 2
Nanotech 2005 Vol. 3
WCM 2005
Nanotech 2004 Vol. 1
Nanotech 2004 Vol. 2
Nanotech 2004 Vol. 3
Nanotech 2003 Vol. 1
Nanotech 2003 Vol. 2
Nanotech 2003 Vol. 3
Nanotech 2002 Vol. 1
Nanotech 2002 Vol. 2
Nanotech 2001 Vol. 1
Nanotech 2001 Vol. 2
MSM 2000
MSM 99
MSM 98
Index of Authors
Index of Keywords
Index of Affiliations
Library Request Form
Shopping Cart
Order Form
 
Publications Publications
Nanotech 2006 Vol. 2
p
 
Technical Proceedings of the 2006 NSTI Nanotechnology Conference and Trade Show, Volume 2
Nanotech 2006 Vol. 2
Technical Proceedings of the 2006 NSTI Nanotechnology Conference and Trade Show, Volume 2
 
Chapter 1: Cancer Nanotechnology
 

Development of Tumor Targeting Magnetic Nanoparticles for Cancer Therapy

Authors:R. Ivkov, S.J. DeNardo, L.A. Miers, A. Natarajan, A.R. Foreman, C. Gruettner, G.N. Adamson and G.L. DeNardo
Affilation:Triton BioSystems, Inc., US
Pages:21 - 24
Keywords:cancer, immunotherapy, magnetic nanoparticles, antibodies, thermotherapy
Abstract:111In-ChL6 MAb-linked iron oxide nanoparticles (bioprobes) pharmacokinetics, tumor uptake and the therapeutic effect of inductively heating these bioprobes by an externally applied AMF were studied in athymic mice bearing human breast cancer HBT3477 xenografts. Bioprobe doses (20mg/2.2mg ChL6/ bioprobe), were administered i.v. with 50μg ChL6; a 153 kHz AMF was given 72 hr post injection (pi) for therapy with amplitudes of 1,300, 1,000 or 700 Oersteds. Weights, blood counts and tumor size were monitored and compared with control mice receiving nothing, or AMF or bioprobes alone. 111In-ChL6 bioprobe binding in vitro to HBT3477 cells was 50 to 70% of that of 111In-ChL6. At 48 hours, tumor, lung, kidney, and marrow uptake of the 111In-ChL6 bioprobes were not different from that observed in prior studies of 111In-ChL6. Significant therapeutic responses from AMF/bioprobe therapy were demonstrated. Toxicity was only seen in the 1,300 Oe AMF cohort, with 4 of 12 immediate deaths and skin erythema. Electron micrographs showed bioprobes on the surfaces of the HBT3477 cells of excised tumors and tumor necrosis 24 hours after AMF/bioprobe therapy. This study shows that mAb-conjugated nanoparticles (bioprobes), when given i.v., escape into the extravascular space and bind to cancer cell membrane antigen, so that bioprobes can be used in concert with externally applied AMF to deliver thermoablative cancer therapy.
ISBN:0-9767985-7-3
Pages:893
Hardcopy:$185.00
 
Order:Mail/Fax Form
Special:3 CD Set — 15% off with Free Shipping
Up
nanoPRwire™
nanoPRwire
News Headlines
nano World news
 
 
 
 
px
© Nano Science and Technology Institute     About NSTI | Terms of Use | Privacy Policy | Contact